David Roblin
CEO
Relation Therapeutics
Relation Therapeutics utilizes single-cell multi-omics, functional assays, and machine learning to identify druggable targets and develop therapies for severe diseases, starting with osteoporosis. By integrating high-resolution biological data directly from patient tissue, the company aims to enhance understanding of disease mechanisms and improve treatment outcomes.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$77.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional drug discovery methods often fail to accurately model the complexities of human disease, leading to high failure rates in clinical trials. Current approaches may not fully capture the heterogeneity of patient populations or the intricate relationships between genes, proteins, and cellular functions within diseased tissues. This can result in treatments that are ineffective or have limited efficacy for many patients.
Solution
Relation Therapeutics employs a "Lab-in-the-Loop" approach that integrates single-cell multi-omics, functional assays, and machine learning to identify novel drug targets and develop therapies for severe diseases. The company analyzes high-resolution biological data directly from patient tissue to gain a deeper understanding of disease mechanisms. By combining multi-omic data with machine learning, Relation Therapeutics aims to identify druggable targets and develop therapies with improved efficacy and patient outcomes.
Target Audience
Relation Therapeutics focuses on patients suffering from severe diseases, and their primary customers are pharmaceutical companies and research institutions seeking innovative drug targets and therapies.
Features
- Single-cell multi-omics analysis to characterize disease at the cellular level
- Functional assays to validate drug targets and assess therapeutic efficacy
- Machine learning algorithms to identify patterns and relationships in complex biological data
- Integration of patient tissue data to improve the accuracy of disease models
- Identification of novel druggable targets for severe diseases